Search

Now showing items 1-4 of 4

Prognostic relevance of integrated genetic profiling in acute myeloid leukemia

Huberman, K; Aminova, O; Thomas, S; Dolgalev, L; Van Vlierberghe, P; Racevskis, J; Sun, Z; Fernandez, H; Figueroa, ME; Gönen, M; Patel, JP; Cheng, J; van den Brink, MR; Litzow, M; Gallagher, RE; Ketterling, RP; Viale, A; Socci, ND; Heguy, A; Cherry, A; Vance, G; Higgins, RR; Levine, RL; Abdel-Wahab, O; Melnick, A; Tallman, MS; Paietta, E; Ferrando, A; Luger, S; Rowe, JM; Lazarus, HM (2012)

BACKGROUND: Acute myeloid leukemia (AML) is a heterogeneous disease with respect to presentation and clinical outcome. The prognostic value of recently identified somatic mutations has not been systematically evaluated ...

Acute myeloid leukemia with translocation t(8;16) presents with features which mimic acute promyelocytic leukemia and is associated with poor prognosis

Diab, A; Zickl, L; Abdel-Wahab, O; Jhanwar, S; Gulam, MA; Panageas, KS; Patel, JP; Jurcic, J; Maslak, P; Paietta, E; Mangan, JK; Carroll, M; Fernandez, HF; Teruya-Feldstein, J; Luger, SM; Douer, D; Litzow, MR,; Lazarus, HM; Rowe, JM; Levine, RL; Tallman, MS (2013)

Previous small series have suggested that acute myeloid leukemia with t(8;16) is a distinct morphologic and clinical entity associated with poor prognosis. We describe 18 patients with t(8;16) AML, including their clinical, ...

Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia

DiNardo, CD; Propert, KJ; Loren, AW; Paietta, E; Sun, Z; Levine, RL; Straley, KS; Yen, K; Patel, JP; Agresta, S; Abdel-Wahab, O; Perl, AE; Litzow, MR; Rowe, JM; Lazarus, HM; Fernandez, HF; Margolis, DJ; Tallman, MS; Luger, SM; Carroll, M (2013)

Cancer-associated isocitrate dehydrogenase (IDH) mutations produce the metabolite 2-hydroxyglutarate (2HG), but the clinical utility of 2HG has not been established. We studied whether 2HG measurements in acute myeloid ...

CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900

Gönen, M; Sun, Z; Figueroa, ME; Patel, JP; Abdel-Wahab, O; Racevskis, J; Ketterling, RP; Fernandez, H; Rowe, JM; Tallman, MS; Melnick, A; Levine, RL; Paietta, E (2012)

We determined the prognostic relevance of CD25 (IL-2 receptor-α) expression in 657 patients (≤ 60 years) with de novo acute myeloid leukemia (AML) treated in the Eastern Cooperative Oncology Group trial, E1900. We identified ...